Genitrix has launched Libromide, the first licensed formulation of potassium bromide for the treatment of canine epilepsy, following what the company believes to be the largest ever trial of dogs suffering from epilepsy.

Genitrix says the availability, for the first time, of a licensed formulation of potassium bromide should give veterinary surgeons and pet owners the reassurance that the rigorous authorisation process provides.  It ensures, for instance, that the product has been developed especially for dogs and that it is manufactured in accordance with EU regulations. It also ensures that the product has been extensively and independently trialled, proven to be efficacious without adverse reactions, and that the necessary pharmacovigilance is in place to support it.  

The company also says that the availability of a licensed product paves the way for more comprehensive information to be provided to veterinary surgeons on the use of potassium bromide in treating seizures.  The Veterinary Medicines Directorate (VMD) imposes restrictions on educational materials supplied by manufacturers of unlicensed products, an approach which has created a 'knowledge gap' among many veterinary surgeons in general practice, according to some canine epilepsy experts.

Libromide tablets are intended for use in epileptic dogs which have already commenced therapy with Phenobarbital. Phenobarbital acts to increase the effects of the GABA inhibitory neurotransmitter in the central nervous system.  Potassium bromide is synergistic with Phenobarbital and raises the seizure threshold level in epileptic dogs. 

Libromide is classified as POM-V and will be available in 325 mg tablets in packs of 100 and 500 tablets.

Rodolfo Cappello DVM PhD DipECVN MRCVS, RCVS and European Specialist in Neurology and Neurosurgery, Head of Neurology Services at North Downs Specialist Referrals, Surrey, said: "I've been successfully using potassium bromide for the treatment of epilepsy in dogs for over 15 years.  The main problem has been that it's not been licensed as a medicine.  With the launch of Libromide, potassium bromide finally achieves the status of an approved pharmaceutical.  We will now be able to monitor quality, efficacy and side effects which will enable us to offer a more professional approach to the treatment of seizures."

Howard Wilder, founder and managing director of Genitrix, added:  "Canine epilepsy is an all too common disease with estimates suggesting it affects four in every hundred dogs in the UK.  It's also an illness which is not well enough understood with the lack of up to date information available to veterinary surgeons being a contributing factor.

We felt there was an opportunity to bring a licensed product to market and have invested hundreds of thousands of pounds in the process of development and trialling Libromide.  We're delighted to make it available to veterinary professionals and hope its launch will be the first step in improving treatment approaches for this distressing disease."

Virbac - manufacturer of Effipro - has launched the 'Flea Free Zones' campaign to help practices fight back against retail competition in the flea control market.

The company says that with an on-pet flea product market estimated to be worth well in excess of £64 million, and an estimated 20 million cats and dogs in the UK, vets are well positioned to improve their revenues and provide excellent customer service, by promoting flea control to all of their customers.

However, according Dr Rachel Crowe, Effipro Product Manager, much of this business is currently going through retail channels: "Many pet owners have become used to purchasing their flea treatment from retail outlets, mainly due to cost, and no longer distinguishing between a brand bought from a vet and one bought from a supermarket.

"As a dedicated veterinary business, Virbac is focussed on supporting and increasing business within veterinary practices. Our 'Flea Free Zones' campaign is a practice support package designed to help promote initial purchase, as well as long-term client loyalty. We know that pet owners often turn to their vet or vet nurse for advice, but then purchase treatments elsewhere.

"With Effipro, practices have the performance of fipronil but at a highly affordable price, and we believe this promotion will help vets grow their share of the flea control market." 

The campaign is designed to get clients purchasing flea treatments from their vet and encourage repeat purchases from the practice.

Dr Crowe said: "The beauty of Effipro is that it has a broad range of products, packs and price flexibility. In particular the single pipette from the Practice Pack is proving a very popular point of entry for the owner, especially as an initial trial purchase. Also included in the promotional campaign is an Effipro loyalty scheme, which provides an incentive to keep clients coming back and literature to assist practice staff to answer customer queries about flea control.

"Just one spot-on treatment range also means there is no confusion with POM-V alternatives, so loyalty to Effipro is easier to retain within the practice. And with the added option of purchasing award winning Indorex environmental insecticide spray, clients now have a complete flea control solution available from their vet practice. So with both products being supported by prominent promotional campaigns, there hasn't been a better opportunity than this for vets looking to capture a bigger share of customer spend on flea treatments."

To learn more about Virbac's Flea Free Zones campaign contact your local Virbac territory manager or call Virbac on 01359 243243.  

Virbac has launched a reformulated dental chew for dogs.

The company says the new VeggieDent chew is thicker in order to prolong the chewing time, but retain its palatability and characteristic Z shape, designed to facilitate prehension and enhance the mechanical cleaning action.

Product manager Chris Geddes MRCVS says the longer chewing time means increased contact between teeth and chew: "Optimum plaque removal is achieved by physical abrasion of the tooth surface during chewing. What is important is both the nature and the duration of contact between tooth and chew. These chews have been reformulated to optimise both of these factors.

"Whilst regular tooth brushing is always the gold standard, the chews provide enhanced plaque removal above brushing alone, and are particularly suited for those difficult cases where brushing is not possible".

"Many dogs are offered treats or chews during the day with limited nutritional or health benefits. VeggieDent chews are highly palatable, natural, and meat-free. They help to sustain tooth and gum health and are a great way to encourage the provision of treats that have a health benefit".

The chews are available in packs of 15 in sizes suitable for small, medium and large dogs and can be obtained from your veterinary wholesaler. Look out for a relaunch promotion coming soon. For further information please speak to your Virbac Territory Manager, phone Virbac on 01359 243243, or email enquiries@virbac.co.uk.

Alstoe Animal Health has introduced a new, palatable joint nutrient supplement for horses.

According to the company, the benefits of feeding equine joint nutrient supplements to assist with maintaining mobility and supporting health joint function has been well documented, but until now, their flavours have often had to be disguised by mixing them into the feed in an attempt to ensure compliance.

Easeflex Equine palatable pellets include alfalfa, an equine favourite which has been used in the USA for some time, and shown to be readily accepted by horses, without the need to mix with the feed.

Alstoe says Easeflex Equine contains high levels of glucosamine hydrochloride and chondroitin sulphate, which are important in the production of glycosaminoglycans, and which have chondroprotective properties that aid in the natural renewal of cartilaginous tissue. Easeflex Equine palatable pellets also include MSM (methyl-sulphonyl-methane), a source of bioavailable sulphur, a key component of connective tissue and important in the synthesis of articular cartilage. Antioxidants are also present to help prevent damage by free radicals, as well as the essential trace minerals, copper, zinc and manganese.

Easeflex Equine palatable pellets can be fed to horses, ponies and donkeys of any age. The company recommends initial daily feeding of a double loading quantity for the first four to six weeks, thereafter reducing to a maintenance level or as directed by the veterinary surgeon. The amount of pellets to be fed depends on the weight of the animal, one small scoop containing 28g of pellets can be a daily dose for a horse of up to 450kg. Easeflex Equine palatable pellets are available in 1.7kg and 4.54kg tubs.

Dutch veterinary oncologist Camille De Ley has launched BraveBites, a snack designed to support canine cancer patients, in the UK. 

BraveBites contains protein, fish oil (rich in omega-3) and prebiotics.

The snack, which was developed with a veterinary nutritionist, has a soft texture and high palatability.

Camille, who worked for a year at Fitzpatrick Referrals, said: “In dogs undergoing cancer treatment, decreased appetite and weight loss are common.

"They negatively affect both prognosis and quality of life.

“Owners were constantly asking what they could still give their dog when food refusal started.”

Camille says that in a field test across 40 veterinary clinics in Belgium and the Netherlands, over 95% of oncology patients accepted the snack well, with a reported improvement in appetite and quality of life

BraveBites is available direct to vets, with educational material, client brochures, and quality-of-life monitoring tools.

http://www.bravebitespetfood.com 

Companion Care Vets has opened its first new standalone joint venture surgery in Ayr, Scotland. 

At 3,071 sq ft the £300,000 surgery is the largest of the groups' 86 strong network and is the first standalone surgery to be opened under the joint venture partnership model that has been in place since 2001.

The surgery is located in a retail park environment, to give easy access for clients and their pets. It is a full service practice, which Companion Care says is fitted with all the latest equipment, including digital x-ray machines and a full operating suite.

Managing Director, Jane Balmain, said: "The opening of our first new standalone surgery in Ayr is a real milestone for us as a business because it opens up our offering to the vets and veterinary nurses who are interested in a joint venture partnership, but whose preference is to have a more traditional looking standalone surgery."

Whilst the Ayr surgery is standalone in its own right, due to the unique relationship Companion Care Vets has with Pets at Home, the surgery works in close partnership with the local Pets at Home store. This will help to drive client registrations and business development and further enable Pets at Home to develop the full pet care experience for its customers.

Jane added: "We believe that this new venture offers any potential partner the best of both worlds: a superb in-store surgery with footfall of thousands of customers a month, or a standalone new surgery linked to local store network to develop the business. I don't believe any other company can offer this unique proposition."

Veterinary surgeon, and joint venture partner of the Ayr surgery, Kirstin Fyfe says, "I am extremely proud to be opening the first standalone surgery alongside the Companion Care team and the facilities available to my team and I and local pet owners are fantastic. The latest equipment, coupled with a spacious and modern waiting area and the convenience of our location is what makes this a winning formula."

A research project funded by The Horse Trust has found that various types of ocular tumours can be successfully treated with mitomycin C, a cytotoxic antibiotic isolated from a bacterium.

The research concludes that mitomycin C offers a safe and cost effective alternative to current treatment options such as surgery and radiation.

The research project was led by Fernando Malalana, while working as The Horse Trust's Clinical Scholar in Equine Internal Medicine at University of Liverpool. Fernando is now working as a Clinician Teacher in Equine Internal Medicine at the university.

Ocular tumours are more difficult to treat than tumours in other parts of the horse's body due to the risk of damaging the eye. In the study, Malalana investigated the use of mitomycin C in treating ocular squamous cell carcinoma, the most common ocular tumour in horses, and occular sarcoids, skin tumors that frequently affect the eyelids .

Mitomycin C is an antibiotic isolated from a bacterium, Streptomyces caespitosus. It is known to have cytotoxic effects and has been used to treat tumours in horses before, but only in combination with surgery.

Currently, the main method of treating ocular squamous cell carcinoma is by removing the tumour surgically or with radiation. Both treatments are costly and have a number of associated risks. There is also the risk of damage or scarring to the eye.

Fourteen horses with ocular squamous cell carcinoma, three of which were affected bilaterally, were included in the study. Mitomycin C was applied to the conjunctival sac of the affected eye; in some of the cases the treatment was combined with surgery. Malalana found that of the 8 eyes treated with mitomycin C alone, clinical resolution occurred in 6 cases. Of the 9 eyes treated with both surgery and mitomycin C, clinical resolution occurred in 7 cases.

Mitomycin C was also used to treat various types of sarcoids found in the eye. Currently, the most effective treatment for occular sarcoids is radioactive wire. However, radioactive wire treatment is not ideal as it is expensive, only offered in two locations in the UK, and has potential health risks to the vet applying the wire due to exposure to radioactivity.

Six horses and two donkeys with occular sarcoids, including one horse that was affected bilaterally, were treated with mitomycin C, which was injected directly into the tumour. Malalana found that of the nine nodular and fibroplastic occular sarcoids treated with the antibiotic, all were completely cleared. However, the vets did not have good results with verrucous sarcoids.

Malalana said: "The results of this research should offer hope to the owners of horses that have eye tumours. We have already been contacted by vets from across Europe to find out more information about this treatment and hope that it will be offered to more horses with occular tumours in the future".

Vets at the University of Liverpool are now testing the use of mitomycin C on other tumours that are difficult to treat surgically, including melanomas near the horse's anus. So far, two cases have been treated, but it is too early to tell whether treatment has been successful.

Malalana's research has been submitted to Veterinary Ophthalmology journal.

Pedigree has announced that it has raised over £160,000 to help the thousands of dogs abandoned every year in the UK, through its charitable initiative, The Pedigree Adoption Drive 2011.

Pedigree says its fundraising comes at a crucial time, as rescue centres' facilities across the country are severely suffering under the strain of the highest level of dog abandonment in over a decade. 

The Pedigree Adoption Drive, which launched in mid-October, aims to raise awareness of the ever-increasing issues of dog abandonment and funds for the hundreds of rescue centres across the country that work tirelessly to find these dogs new loving homes. 

Now in its fourth year, the campaign called upon dog lovers everywhere to show their support, by taking part in the world's first virtual dog walk around the web. In addition, consumers got involved in a host of other activities - donating via text message and online, to help the Drive reach this year's grant total. 

The funds raised this year will be distributed through grants to 90 rescue homes across the country - including three special grants of £15,000 given to Bath Cats and Dogs Home, £20,000 given to North Clwyd Animal Rescue and £25,000 given Birmingham Dogs Home.  Every grant will be put towards projects aimed at making tomorrow better than today for dogs - including the refurbishment of dilapidated kennel blocks, desperately needed veterinary facilities and the supply of essential surgical equipment.

TV presenter and vet Steve Leonard, who is the ambassador of this year's campaign, said: "The money raised from this year's Pedigree Adoption Drive is a great example of how we can achieve so much together to help take steps towards tackling the issue of dog abandonment.  The grants awarded to rescue centres this year will make a big difference in helping to find many rescue dogs, the loving homes they deserve."

Katie Wragg, Pedigree Adoption Drive Brand Manager said: "In the last four year's we've raised over £1million for rescue centres supporting the country's abandoned dogs and despite the tough economic climate, the amazing public reaction has enabled us to really make a difference to the lives of abandoned dogs across the UK and help give them  a bright future."

For more information on the campaign log on to: http://www.pedigreeadoptiondrive.com/

Royal Canin has launched two new skincare diets.

'Hypoallergenic Wet' is a wet adaptation of its 'Hypoallergenic' range of diets, providing variety for the nutritional management of dogs with adverse food reactions. 'Anallergenic' dry food is for the dietary management of dogs with even the most severe dietary allergy.

'Hypoallergenic Wet' contains soy protein hydrolysate, so it can either be fed as a complete diet or interchanged and used as an addition to Hypoallergenic, Hypoallergenic Moderate Calorie or Hypoallergenic Small Dog. The wet food, available in a 400g can, can be recommended for short term feeding (for an elimination diet strategy) or for the lifelong nutritional management of dogs with adverse food reactions. Royal Canin says it is designed to be highly digestible through its low molecular weight peptides and is also appropriate for the dietary support of dogs with inflammatory bowel disease, chronic diarrhoea and Exocrine Pancreatic Insufficiency (EPI).

'Anallergenic' follows in the footsteps of Hypoallergenic but goes further - offering both hydrolysed proteins and a pure carbohydrate source, to which exposure is limited and therefore allergy would be rare. The diet comprises a unique protein source composed exclusively of free amino acids and very low molecular weight oligopeptides. Much like the Hypoallergenic range, Anallergenic is also formulated with essential fatty acids to help support skin health and a complex of nutrients to help maintain the barrier effect of the skin.

The fully balanced diet - suitable for the nutritional support of adult dogs either short or long-term - has proven results with 100% of dogs in a Royal Canin study showing significant improvement in their skin condition.

Gudi Stuttard BVSc MRCVS, one of Royal Canin's Veterinary Support Managers, said: "These two new products join our well-established 'Hypoallergenic' range, as well as our recently launched 'Skin Care' diets - for the nutritional management of dogs with dermatosis unrelated to food intolerance or allergy.

"By building on our portfolio of veterinary skin care diets, we aim to further strengthen our DermAlliance campaign, which is dedicated to assisting in the improvement of skin care knowledge in general veterinary practice."

Please visit www.royalcanin.co.uk for more information.

Bristol Vet Specialists has launched a chronic pain clinic for cats and dogs in the South West of England, led by Jo Murrell, European Specialist in Anaesthesia and Analgesia.

The clinic offers Specialist care primarily for patients with osteoarthritis pain, but also those with chronic pain caused by other conditions, such as cancer, dental and ear diseases, spinal disease and feline hyperaesthesia syndrome.  

BVS says cats and dogs coming to the clinic will get the highest level of care with a specialist assessment from Jo, who also also works closely with the orthopaedic and neurology services to offer a global and holistic approach.

The assessment will identify signs of chronic pain, gauge the severity, and also evaluate the impact of the condition on the animal’s quality of life.

Jo says it is important to identify these conditions as early as possible, as instigating pain management early helps to dampen down pain signals and reduce overall upregulation of the pain pathways.

To that end, Jo uses validated clinical metrology instruments (owner questionnaires) to measure the severity of pain, especially during initial appointments.

Should a condition be detected, Jo and her team will be able to offer pharmacotherapy, intra-articular and epidural injections and acupuncture.

Jo also works closely with physiotherapists and hydrotherapy services, which can be used as adjunctive therapy.

Jo said, said: “Many cats and dogs will experience chronic pain. These cases need to be thoroughly investigated to ensure that the cause of pain is properly identified and treatment quickly provided. We are very pleased to be able to open our new chronic pain clinic for cat and dog owners in the South West today to provide this essential service.”

https://www.bristolvetspecialists.co.uk 

IVC has opened Blaise Veterinary Referral Hospital, one of the largest referral centres in the UK, with a capacity to treat up to 10,000 pets a year.

Located on the Longbridge regeneration site near Birmingham, Blaise Referrals is IVC's first purpose-built, multi-disciplinary hospital in the UK and the company says it provides a blueprint for its future hospitals, with a clinician-led building design and a nurse-led clinical floor, both of which are fairly new practices for the profession.

Blaise Referrals will accept patients from first opinion practices across the UK and offer a wide range of services including orthopaedic and soft tissue surgeries, neurology, cardiology, internal medicine.

The hospital has a state-of-the art intensive care unit with a dedicated ICU team which can support other hospital departments with its advanced facilities.

The 36,000 square foot hospital also boasts a 1.5T Siemens MRI, a 64 slice Siemens CT scanner, multiple ultrasound machines and both fixed and digital radiography machines.

The team at Blaise is led by clinical director Former Member and hospital director Julie Davis, both of whom have been hard at work over the last year amassing a team of veterinary professionals across multiple disciplines including Jacques Ferreira as head of anaesthesia, Jennifer Raj as head of internal medicine and Carlo Anselmi as head of diagnostic imaging.

Andy said: “We’ve worked incredibly hard to get to this point and I know I speak on behalf of the whole team here at Blaise when I say we are thrilled to officially be able to welcome pets and owners from all around Birmingham and the Midlands.

“Recent years have seen an ever-increasing need for specialist referral services in the veterinary industry and we are here to answer that demand by providing excellent high-quality and professional care for pets who need it.”

www.blaise-referrals.com

Hill's Pet Nutrition has reported some early results from its '60 Tonnes in 6 Months' pet weight loss campaign, which started 2 months ago.

The company says that although there is only preliminary data available from 33 practices, it's clear that the campaign is working, with each practice involved reporting on average over 10 Kg weight loss from their patients. However, many practices are holding on to send in results until their patients have reached their final targets, so more data is expected. 

Hill's says that some practices have had great success using its PR kit, generating positive coverage in local newspapers. Sara Locke, Associate Customer Marketing Manager is reminding practices that January is the traditional time for 'dieting fever' to hit the headlines after the indulgencies of the festive season. She said: "If you have one of our PR kits, don't forget to send out your pro forma press release - it's not a big task to customise it with your practice details and you could find yourself making a big splash locally at a time when we know interest will be heightened."

As part of the campaign, Hill's has also produced a series of nurse webinars, the last of which was on exercise and rehabilitation programmes for overweight pets and contains tips on how to develop a personalised exercise programme that fits with the owner's lifestyle and reflects the pet's capabilities and level of mobility. The webinar can be viewed here: https://hillsvet.webex.com/hillsvet/lsr.php?AT=pb&SP=EC&rID=13881732&rKey=E1182C100CB53476

Further information is available from local Hill's Territory Managers or by calling Hill's on 0800 242438 or in ROI 1 800 626002.

Ceva Animal Health, manufacturer of Feliway and Adaptil, is making a last call for nominations for its awards for animal welfare, which must be received by 27^th January 2012.

The inaugural awards, which take place during WSAVA/BSAVA/FECAVA Congress in Birmingham in April, formally recognise veterinary professionals and individuals who have gone the extra mile to improve animal welfare both in practice and beyond. The awards feature three categories: 

• Chris Laurence Vet of the Year Award - this award recognises a veterinary surgeon who is following in Chris' footsteps by consistently demonstrating their commitment to the continued improvement of animal welfare
• Welfare Nurse of the Year Award - this award is for a veterinary nurse who has shown real commitment to improving and championing good animal welfare
• Pet Lovers' Welfare Award - this award is open to all individuals involved in the care of animals, whether working in practice, charities or dedicating their spare time to improving animal welfare

Prizes include a trip to New Zealand WSAVA in 2013 for the winner of the Chris Laurence Vet of the Year Award, a trip to a European Animal Welfare Congress for the winner of the Welfare Nurse of the Year Award and £1,000 worth of travel vouchers for the winner of the Pet Lover's Welfare Award.

Nomination forms can be downloaded from www.ceva.co.uk. Nominations should consist of full details about why the nominee deserves to win. Judging will be based on support materials such as case studies, examples and pictures, demonstrating the nominee's commitment to animal welfare. Anyone, whether a veterinary professional, pet owner or animal lover can nominate. All those who have nominated someone for an award will be entered into a prize draw to win £250 of high street vouchers.   

For further information, telephone Ceva Animal Health on 01494 781510, email welfare.awards@ceva.com or contact your local Ceva territory manager.